CUBEBIO to present its cancer self-diagnostic device at Arab Health 2020

CUBEBIO is a biomedical company dedicated to research and development of cancer diagnostic biomarkers and in vitro diagnostics. Our capital is USD 15 million, and we possess more than 30 patents in relation to cancer diagnosis. We have developed the world’s first self-diagnostic device capable of early cancer detection by using urine through the analysis of more than 9,000 pieces of dissertations over the last 8 years.

CUBEBIO’s cancer self-diagnostic device consists of an analyzer (the size of a toaster) and a sensor (the size of a USB flash drive). The device can detect 8 major cancer types (Breast cancer, Colorectal cancer, Lung cancer, Liver cancer, Stomach cancer, Pancreatic cancer, Prostate cancer, and Bladder cancer), which account for about 2/3 of cancer incidence and mortality rates worldwide, at an early stage.

Cancer is the second most life-threatening disease around the world. In 2018, the number of new cancer cases was 18.1 million, nearly twice the entire population of the UAE, while the number of cancer deaths was 9.6 million. Treatment success rate and recovery rate, however, become significantly high when cancer is detected early. With this in mind, CUBEBIO’s cancer self-diagnostic device allows anyone to check their cancer status frequently and conveniently, thereby providing a practical solution to the underlying issue of cancer.

We have been proceeding with a global project for the supply of the cancer self-diagnostic device. We have signed export contracts worth USD 4.5 billion with Russia and 10 more countries.

The global project would not have been made possible without the help of our partners. They are Asan Medical Center, BHflex/DKT, Samsung Securities, Union for International Cancer Control (UICC), and National Medical Research Radiology Center (NMRRC).

Asan Medical Center is the most popular hospital in South Korea with the highest number of outpatients and visitors as well as the No. 1 hospital in the number of surgeries on 9 major cancers and their success rate. The number of international patients visiting the hospital (about 20,000 per year) proves Asan Medical Center’s position as one of the most internationally reputable hospitals. CUBEBIO has conducted clinical trials for cancer diagnosis through cancer patients’ urine samples and has signed a contract for joint research and development of cancer diagnostic technology with Asan Medical Center.

BHflex and DKT are companies specializing in the manufacturing of circuit boards, which are key parts of electronic products, such as smartphones, laptops, and wearable devices. Their major customers include Apple, Samsung Electronics, LG Electronics, Sony, Huawei, and Xiaomi. These companies also possess large factories in South Korea, China, and Vietnam. CUBEBIO has signed contracts with BHflex and DKT for mass production of the cancer self-diagnostic device, and production facilities have been established in South Korea and Vietnam.

Samsung Securities is South Korea’s top financial investment company affiliated with Samsung Group and has served as an underwriter for the management of IPOs of domestic and foreign biomedical companies worth hundreds of millions of dollars. Samsung Securities has been selected as CUBEBIO’s lead underwriter. The company fulfils the task of CUBEBIO’s listing on the Korean Stock Exchange and deals with the sale of foreign securities when CUBEBIO is listed on foreign stock exchanges. As well, Samsung Securities provides consultations on CUBEBIO’s finance.

UICC is the largest and oldest international cancer organization with over 1,150 members and 58 partners across 173 countries. UICC holds annual international health platforms, such as the World Cancer Leaders’ Summit and the World Cancer Congress, by inviting highly influential figures, like Presidents, First Ladies, Royal Families, Health Ministers, etc. CUBEBIO has signed a Patron partnership agreement with UICC in which Patron partnership is the highest partnership level and thus has become the first UICC Patron partner as a small- and medium-sized enterprise in the world. In addition, CUBEBIO and UICC have jointly developed a program, called ‘Cancer Early Detection and Self-Diagnosis,’ to globally promote the importance of early detection of cancer and the concept of cancer self-diagnosis.

NMRRC is the Federal State Budgetary Institution of the Ministry of Health of the Russian Federation and the largest medical center in the field of oncology, radiology, and urology. Hertsen Moscow Oncology Research Institute of NMRRC is the oldest cancer clinic in Europe. CUBEBIO has attended a conference on its cancer self-diagnostic device at the Institute and has been conducting the customization of its product with Russian cancer patients’ urine samples for the localization. CUBEBIO has signed a contract for the export of the cancer self-diagnostic device with the firm that has received a power of attorney from NMRRC.

CUBEBIO’s international standing has been greatly enhanced through active support of our partners. As we are planning to get listed on the NASDAQ, we are expecting to see a significant increase in the company’s value.

CUBEBIO is to participate in Arab Health 2020 by setting up a booth (the size of about 100m²) with the cancer self-diagnostic device. Our booth is designed in such a way that the cancer self-diagnostic device can be used in various places, such as home, hospital, pharmacy, coffee shop, office, and bank, due to its portability. Thus, we intend to show our company’s mission of creating a new global culture where people are empowered to take responsibility for their own health and the health of their families by self-diagnosing cancer at the early stage quickly, easily, and accurately, regardless of location or time.

We have been negotiating with large companies in the US, Europe, the Middle East, China, and Southeast Asia for the supply of the cancer self-diagnostic device. By starting with Arab Health in the Middle East, we are planning to join other exhibitions in the US and Germany to ensure that our product can be supplied to broader audiences.